Global Stem Cells Group (GSCG) is Proud to Announce Its Latest Cellgenic Exosome Product
Global Stem Cells Group (GSCG), a renowned leader in regenerative medicine, is thrilled to unveil its groundbreaking product, Cellgenic Lyophilized Exosomes – The Regen Series. We believe this product is set to revolutionize orthopedic and pain management applications, offering a remarkable potential for tissue regeneration in damaged areas of the body. Derived from human umbilical cord mesenchymal stem cells, Cellgenic Lyophilized Exosomes is a multifaceted solution that holds promise in addressing a wide range of ailments.
Cellgenic Lyophilized Exosomes contain a synergistic blend of essential components, including peptides, coenzymes, minerals, amino acids, vitamins, and UV radiation-reducing agents. These elements not only facilitate tissue regeneration but also make this product an exceptional option for skin revitalization. By utilizing this remarkable product, individuals may experience reduced pain levels.
A Revolutionary Product
Cellgenic Lyophilized Exosomes demonstrate unparalleled versatility and efficacy. Notably, this product requires no special storage conditions, enabling customers to utilize it conveniently at full capacity. Designed to combat inflammation and facilitate tissue repair, this targeted solution can significantly alleviate chronic pain, providing relief to those who have struggled to find effective solutions.
The exosome technology utilized in this product involves the freeze-drying of extracellular vesicles (EVs), which are kept separate from the mesenchymal stem cell cultures expanded in the laboratory. The Lyophilized Exosomes are then reconstituted with saline in front of the patient, just before use. This approach has proven to be highly effective in reducing inflammation and managing pain.
Global Stem Cells Group Remains a Leader in the Industry
One of the things that has helped set Global Stem Cells Group apart from the competition is their willingness to think in innovative ways that others simply do not. For example, the brand-new Lyophilized Exosome product can be shipped anywhere around the world without refrigeration. This allows for the possibility of getting it out to the places that truly need it without the burdensome ordeal of having to maintain the medication at a certain temperature. This is a problem for many medications, but GSCG has made sure that its products are more versatile than that.
Growing Faster Than Ever Before
Global Stem Cells Group has a lot going for it as far as its growth trajectory is concerned. They already have multiple offices around the globe, and they are always looking to expand their outreach by opening offices wherever it is prudent to do so. We believe the new product, Lyophilized Exosomes – The Regen Series, is set to strengthen GSCG’s position as a global leader in the regenerative and restorative medicine space for now and long into the future.
Benito Novas, CEO of Global Stem Cells Group, expressed his excitement about the company’s growth and stated, “Our goal at Global Stem Cells Group is to develop the most effective regenerative products on the market. Our new product line of lyophilized exosomes is a testament to our commitment to developing cutting-edge products with great clinical utility.”
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a world-renowned leader in regenerative medicine, specializing in innovative solutions that harness the power of stem cells for therapeutic applications. With a global network of offices and an unwavering commitment to excellence, GSCG continues to shape the future of regenerative and restorative medicine through groundbreaking products and advanced treatment protocols.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Uncategorized
Global Stem Cells Group announces participation in IV Jornadas de Actualización Medestética 2023
Global Stem Cells Group (GSCG), a leading provider of regenerative medicine solutions, is proud to announce its participation in the IV Jornadas de Actualización Medestética 2023 through the International Society for Stem Cell Association (ISSCA), its educational division and also with its line of Cellgenic Exosomes products.
The congress, which will take place on March 30th and 31st at Paseo La Plaza in Buenos Aires, Argentina, will provide a platform for ISSCA to share its knowledge and expertise in regenerative medicine with the Argentine medical community.
ISSCA is a multidisciplinary community of physicians and scientists whose mission is to advance the science, technology, and practice of regenerative medicine to treat disease and lessen human suffering. The organization has been at the forefront of promoting excellent and standardized regenerative medicine and will continue to participate in similar medical events such as this one.
The Global Stem Cells Group will also have a booth at the event to showcase its products, Cellgenic Exosomes, in its two presentations: “Cellgenic Lyophilized Exosomes” and “Cellgenic Flow Exosomes.” Additionally, it will provide guidance on how to use the products on patients.
As part of the program, ISSCA faculty members will be giving presentations and holding practical workshops to demonstrate the latest applications of regenerative medicine. The ISSCA program will cover all aspects of regenerative medicine including guidelines and clinical protocols.
“We are excited to take part in this congress and share our expertise, knowledge, and cellgenic exosome product line with the Argentine medical community,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA.
The IV Jornadas de Actualización Medestética 2023 will feature various ISSCA-certified doctors and experts as speakers, including:
Dr. Silvina Pastrana
Dr. Pastrana heads the ISSCA chapter in Argentina and serves as the medical center’s director. “Traditional, advanced, and cutting-edge anti-aging and rejuvenation medicine” will be her theme at this congress. Dr. Silvina will deliver a 40-minute summary of all the regenerative medicine and cell therapies that are now being used to postpone aging and enhance quality of life. therapies using NK cells, fluid and lyophilized exosomes, allogenic therapies, and autologous cells.
Dr. Andrea Lapeire
Dr. Lapeire is a doctor of aesthetic medicine with advanced degrees in environment, homotoxicology, biological medicine, and obesity. She will speak on alopecias: traditional and cutting-edge. Exosome Use and Biological Stimulation Fundamentals.
Prof. Dr. Julio Ferreira
Professor Ferreira is from Argentina and is a professional cosmetic surgery and aesthetic medicine expert. He is a university professor of medicine and is the president of the South American Academy of Aesthetic Surgery. He will cover regenerative therapies in rejuvenation and facial harmonization in his lecture.
Dr. Alfonso Ciancaglini
A specialist in Medical Clinic and regenerative medicine, Dr. Alfonsoi is a member of the International Society For Cellular Therapy Application and holds a certification from the Stem Cells Group. His presentation will discuss the use of regenerative medicine to treat venous ulcers.
Benito Novas
Benito Novas is the Head of Public Relations for the International Society for Stem Cell Application from the USA. He is the senior marketing consultant and founder of “Estética marketing INC” as an Author, he has authored several books among them: Su clinica este’tica. Lo que dicen sus pacientes” Marketing Digital en su Clinica Estetica” and “Marketing en Tiempos de Crisis” for more information on Novas you can check on www.benitonovas.com. In this congress. Benito Novas will be covering Digital Marketing in Cash-based practices.
ISSCA at Global Perspective.
ISSCA has been at the forefront of promoting excellent and standardized regenerative medicine. For more information and updates. visit us at https://www.issca.us/
The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research and publications.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Uncategorized